Top related persons:
Top related locs:
Top related orgs:

Search resuls for: "Ter Haar"


3 mentions found


Dr. Gert ter Haar, a specialist in short-muzzled animals at the AniCura veterinary hospital, widened her nostrils and performed other procedures to improve her breathing. Dogs are being bred for their looks, but people tend to forget about their health, said Ter Haar, who recommended potential pet owners should consult a vet before buying. On many, many organs", Dr. Ter Haar said. Dr. Ter Haar said pugs and French bulldogs are mostly affected, although larger dogs such as boxers and chows can also suffer from overbreeding. Dutch Minister of Agriculture and Nature Piet Adema has drafted a legal change to ban harmful characteristics after a transitional period during which owners of overbred pets will be exempt.
Persons: XXL Pablo, Read, Katja, Ilia, Abby, Gert ter Haar, Ter Haar, pugs, Nature Piet Adema, Charlotte Van Campenhout, Bart Biesemans, Anthony Deutsch, Barbara Lewis Organizations: French bulldogs, Agriculture, Nature, Thomson Locations: Utrecht, UTRECHT, Netherlands, Dutch
Advertising agency CEOs are eager to signal their companies' AI expertise to Wall Street. Speaking on this quarter's earnings calls, executives at the world's largest advertising agency groups also outlined some of their recent AI client projects and technology task forces. "What's changed over the last six months is the application of AI through generative AI into the creative process," Read said. Omnicom is running more than 20 projects where it combines Omnicom's historical data with GPT's automation technology, Wren said, though he didn't specify exactly how it was being deployed. That will require more creative assets, Sadoun said on the Publicis earnings call.
A mosaic of human cells inside Vertex Pharmaceuticals' cell and gene-therapy laboratory. The four-story, 267,000-square-foot space is home to Vertex's cell and gene-therapy unit, with about 375 people now residing in the modern-industrial building. That has led to going after unrelated diseases like sickle cell, diabetes, muscular dystrophy, kidney disease, and pain. For instance, Vertex's approach to sickle cell is led by its CRISPR gene-editing program. Vertex PharmaceuticalsThe next test of Vertex's strategy will be an experimental treatment called exa-cel, its CRISPR gene-editing program for sickle cell.
Total: 3